= Solution
\b[A guide specifies the target; the attached <Cas9> machinery determines whether expression changes through <DNA> repair or direct transcriptional regulation.] In <CRISPR genome editing>, a <guide RNA> supplies sequence complementarity to a genomic target adjacent to a suitable <protospacer adjacent motif>. The commonly used <Cas9> from <Streptococcus pyogenes> recognizes an NGG motif, where N is any base. Recognition involves both that motif and pairing between the guide and target <DNA>; an arbitrary complementary sequence is therefore insufficient. In mammalian experiments, a nuclear-localized <Cas9> and guide can be delivered by expression constructs or as a preassembled <ribonucleoprotein>. Multiplexing means supplying several guides, rather than engineering a new DNA-binding <protein> for every target. The original mammalian demonstration combined programmable targeting with endogenous repair to change genomic sequences.<Multiplex genome engineering using CRISPR Cas systems by Le Cong and others>[Cong and colleagues, 2013, abstract and results on endogenous mammalian targeting]{ref}
For a loss-of-function experiment, a cut in an early constitutive <exon> is repaired by <non-homologous end joining> and related end-joining pathways. Insertions or deletions can change the <reading frame>, introduce a premature stop, and trigger <nonsense-mediated decay>. Neither cleavage nor an insertion/deletion automatically proves a <gene knockout>: repair can preserve the reading frame, alternative splicing can bypass the exon, and a mammalian cell may retain an intact allele. Targeting a <promoter> or <enhancer> can instead alter the amount or cell specificity of expression. Two guides can delete a defined regulatory segment, but the resulting junction and possible larger rearrangements need verification. <homology-directed repair> with a donor can introduce an expression tag, repair a mutation, or replace a regulatory sequence; its efficiency depends on cell state and competing repair pathways. Changing the genomic coding sequence can change <protein> activity without changing transcript abundance, so these outcomes should be distinguished.
Expression can also be controlled without cleavage. Catalytically inactive <dCas9> retains guide-directed binding. Positioning it at an appropriate regulatory region can obstruct transcription; recruiting a repressive domain such as <KRAB> strengthens <CRISPR interference> in mammalian cells. Fusing an activation domain, or recruiting several activators, gives <CRISPR activation> at an endogenous promoter. These approaches preserve the coding sequence and permit graded or inducible perturbation, although <chromatin> context and guide position strongly affect performance. Mammalian experiments comparing regulatory fusions established that the same targeting platform can repress or activate transcription.<CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes by Luke A. Gilbert and others>[Gilbert and colleagues, 2013, results on dCas9-based repression and activation in eukaryotic cells]{ref}
The readout should match the proposed mechanism: sequence the target for editing, measure <messenger RNA> by <RT-qPCR>, and measure the <protein> and its biological activity. Use multiple independent guides, a nontargeting guide, delivery-matched controls, and several independently derived clones or a controlled pooled experiment. Rescue with a guide-resistant functional gene supports causality; overexpression rescue alone can have dosage artefacts. Check relevant predicted <off-target effects>, assess cell viability, and distinguish direct expression changes from selection of surviving cell states. A nuclease perturbation can itself activate a DNA-damage response. Thus \b[the strongest conclusion connects a verified molecular perturbation to <RNA>, <protein> and phenotype], rather than treating a guide-dependent phenotype as sufficient evidence.
Back to article page
